Healthcare -
Biotechnology - NASDAQ - US
$ 0.3501
2.97 %
$ 21.8 M
Market Cap
-0.33
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Passage Bio, Inc.
| Current Assets | 78.8 M |
| Cash & Short-Term Investments | 76.8 M |
| Receivables | 0 |
| Other Current Assets | 2.06 M |
| Non-Current Assets | 23.6 M |
| Long-Term Investments | 0 |
| PP&E | 23.1 M |
| Other Non-Current Assets | 463 K |
| Current Liabilities | 19.4 M |
| Accounts Payable | 742 K |
| Short-Term Debt | 3.69 M |
| Other Current Liabilities | 14.9 M |
| Non-Current Liabilities | 21.8 M |
| Long-Term Debt | 21.8 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Passage Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 65.2 M |
| Operating Income | -70.4 M |
| Other Expenses | -5.63 M |
| Net Income | -64.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Passage Bio, Inc.
| Net Income | -64.8 M |
| Depreciation & Amortization | 3.08 M |
| Capital Expenditures | -34 K |
| Stock-Based Compensation | 5.82 M |
| Change in Working Capital | 4.2 M |
| Others | 8.47 M |
| Free Cash Flow | -48 M |
Wall Street Analysts Price Targets
Passage Bio, Inc.
PASG has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PASG does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Passage Bio, Inc.
Sold
0-3 MONTHS
1.69 K USD 1
3-6 MONTHS
513 K USD 1
6-9 MONTHS
175 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
526 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 1 month ago
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided recent business highlights. “We are pleased to report strong performance in 2024 as we meaningfully advanced our PBFT02 program, delivering promising data in FTD-GRN patients showing robust, durable progranulin expression and early evidence of improvement in a disease progression biomarker.
globenewswire.com
- 1 month ago
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
globenewswire.com
- 1 month ago
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data
globenewswire.com
- 3 months ago
Passage Bio assumed with an Outperform at Wedbush
Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage's upsized IPO, but the current valuation looks to be a "deep discount" compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors.
https://thefly.com
- 4 months ago
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.
globenewswire.com
- 5 months ago
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)
globenewswire.com
- 5 months ago
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.
globenewswire.com
- 6 months ago
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases.
globenewswire.com
- 7 months ago
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET.
globenewswire.com
- 7 months ago
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights. “This has been a pivotal quarter for our company, marked by significant momentum in our upliFT-D trial, increased clarity around our strategy to expand PBFT02 into additional adult neurodegenerative indications, and out-licensing of our pediatric lysosomal storage disorder programs,” said Will Chou, M.D.
globenewswire.com
- 8 months ago
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson
globenewswire.com
- 8 months ago
8. Profile
Summary
Passage Bio, Inc. PASG
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 21.8 M
Dividend Yield
0.00%
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Contact
One Commerce Square, Philadelphia, PA, 19103
https://www.passagebio.com
IPO
Date
Feb. 28, 2020
Employees
60
Officers
Mr. Stuart M. Henderson
Senior Vice President of Corporate Development & Investor Relations
Mr. Edgar B. Cale Esq., J.D.
General Counsel & Company Secretary
Dr. Sue Browne Ph.D.
Senior Vice President of Research & Development
Dr. William Chou M.D.
President, Chief Executive Officer & Director
Dr. Karl Whitney Ph.D.
Senior Vice President of Global Regulatory Affairs
Eden Fucci
Senior Vice President of Technical Operations
Ms. Kathleen Borthwick
Senior Vice President, Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer